Clinical Trials
27 trialsA Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
K4CARE-PDAC
Chang Gung Memorial Hospital
SHERLOCK
University Health Network, Toronto
GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer
University of Aarhus
TRACE-BTC
Aarhus University Hospital
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
University Hospital, Montpellier
NIP IT!
University Health Network, Toronto
CLAUDIA
Seoul National University Hospital
DECIPHER
University of Southampton
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TRINITY
Gruppo Oncologico del Nord-Ovest
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
Zhujiang Hospital
Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases
Peking University Cancer Hospital & Institute
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
University Hospital, Montpellier
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
First Affiliated Hospital of Zhejiang University
Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology
Sun Yat-sen University
ECMRD-001
Hebei Medical University Fourth Hospital
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
Guangdong Provincial People's Hospital
Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence
Peking University People's Hospital
Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Tampere University Hospital
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers:A Multicenter Prospective Trial
The First Affiliated Hospital with Nanjing Medical University
AFFORD
Sun Yat-sen University
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
Peking University People's Hospital
Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
The Institute of Molecular and Translational Medicine, Czech Republic
MPM
IRCCS Azienda Ospedaliero-Universitaria di Bologna